Biotech and Pharmaceuticals
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
Nurphoto | Nurphoto | Getty Images Pfizer is ready to move on from Covid. Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. It just might take a while before that bet pays off. Pfizer pitched its […]
Read More
Novo Nordisk CEO says experimental weight loss pill could become a best in class drug
Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday said the company’s experimental weight loss pill, amycretin, could eventually become a best-in-class treatment for obesity. The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy by developing a new generation of treatments for obesity, including more convenient and […]
Read More
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty […]
Read More
Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
The logo of Danish pharmaceutical company is pictured at their headquarters in Bagsvaerd outside of Copenhagen, Denmark on February 1, 2017. Liselotte Sabroe | AFP | Getty Images Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday, after fresh early trial data showed positive results for its new experimental weight loss pill. […]
Read More
Cigna launches effort to cap employer insurance plan spending on weight loss drugs
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Cigna on Thursday unveiled a new effort to expand insurance coverage for weight loss drugs by limiting how much health plans and employers spend on the highly popular treatments each year. […]
Read More
Novo Nordisk shares soar 5% on promising fat reduction demo final results Eli Lilly dips
Jonathan Raa | Nurphoto | Getty Photos Novo Nordisk shares climbed 5% on Thursday early morning, in accordance to LSEG details, hitting a fresh new record highs right after the Danish pharmaceutical big claimed positive early demo data for a new experimental fat loss drug. The company told an investor assembly that the Section I […]
Read More
Biden says Medicare should negotiate prices for at least 50 drugs each year, up from a target of 20
US President Joe Biden speaks during an event at the National Institutes of Health (NIH) in Bethesda, Maryland, US, on Thursday, Dec. 14 2023. Chris Kleponis | Bloomberg | Getty Images President Joe Biden on Wednesday said the federal Medicare program should negotiate prices for at least 50 prescription drugs each year, up from the […]
Read More
Healthy Returns: What to know about CDC’s new Covid recommendations
A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia. Tami Chappell | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The Centers for Disease Control and Prevention announced two major new Covid recommendations last week. The […]
Read More
Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial
This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim, eastern France. Sebastien Bozon | Afp | Getty Images Novo Nordisk‘s blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released […]
Read More
We're in a 'boomer renaissance,' top hedge fund manager says — naming sectors and stocks to play it
Top hedge fund manager David Neuhauser says the world is in a “boomer renaissance” and investors should be betting big on certain sectors that play the theme. The world is aging rapidly, and sectors such as tourism, health care and biotech will benefit from that, according to Neuhauser, who is founder and chief investment officer […]
Read More